Does vascular pathology contribute to Alzheimer changes? - PubMed (original) (raw)
Review
. 2012 Nov 15;322(1-2):141-7.
doi: 10.1016/j.jns.2012.07.032. Epub 2012 Aug 11.
Affiliations
- PMID: 22884479
- DOI: 10.1016/j.jns.2012.07.032
Review
Does vascular pathology contribute to Alzheimer changes?
Raj N Kalaria et al. J Neurol Sci. 2012.
Abstract
In recent years there has been increased interest in whether vascular disease contributes to Alzheimer's disease (AD). This review considers how modifiable risk factors such as hypertension, atherosclerosis, diabetes, dyslipidaemia and adiposity may impact on vascular structure and function to promote neurodegenerative processes and instigate AD. The presence of vascular pathology involving arterial stiffness, arteriolosclerosis, endothelial degeneration and blood-brain barrier dysfunction leads to chronic cerebral hypoperfusion. Pathological changes in human brain and animal studies suggest cerebral hypoperfusion which in turn induces several features of AD pathology including selective brain atrophy, white matter changes and accumulation of abnormal proteins such as amyloid β. Cerebral pathological changes may be further modified by genetic factors such as the apoliopoprotein E ε4 allele. Although tau hyperphosphorylation and tangle formation still needs robust explanation further support for the notion that vascular pathology influences AD changes is provided by the evidence that interventions which improve vascular function attenuate AD pathology.
Copyright © 2012 Elsevier B.V. All rights reserved.
Similar articles
- Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia.
Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Akinyemi RO, et al. Curr Alzheimer Res. 2013 Jul;10(6):642-53. doi: 10.2174/15672050113109990037. Curr Alzheimer Res. 2013. PMID: 23627757 Review. - APOE, vascular pathology, and the AD brain.
Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, Farrer LA. Yip AG, et al. Neurology. 2005 Jul 26;65(2):259-65. doi: 10.1212/01.wnl.0000168863.49053.4d. Neurology. 2005. PMID: 16043796 - Vascular risk factors and the effect of white matter lesions on extrapyramidal signs in Alzheimer's disease.
Park MH, Min JY, Kwon DY, Lee SH, Na HR, Cho ST, Na DL. Park MH, et al. Int Psychogeriatr. 2011 Jun;23(5):780-7. doi: 10.1017/S1041610210002140. Epub 2010 Nov 29. Int Psychogeriatr. 2011. PMID: 21110907 - Axon-glial disruption: the link between vascular disease and Alzheimer's disease?
Horsburgh K, Reimer MM, Holland P, Chen G, Scullion G, Fowler JH. Horsburgh K, et al. Biochem Soc Trans. 2011 Aug;39(4):881-5. doi: 10.1042/BST0390881. Biochem Soc Trans. 2011. PMID: 21787317 Review.
Cited by
- Peripheral inflammation is associated with brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease.
Liang N, Nho K, Newman JW, Arnold M, Huynh K, Meikle PJ, Borkowski K, Kaddurah-Daouk R; Alzheimer’s Disease Metabolomics Consortium. Liang N, et al. Sci Rep. 2024 Jul 29;14(1):17423. doi: 10.1038/s41598-024-67177-5. Sci Rep. 2024. PMID: 39075118 Free PMC article. - VasCog 2023: 20 years of research on vascular behavioural and cognitive disorders.
Gustafson DR, Kalaria R, O'Brien J, van den Brink H, Hilal S, Marseglia A, Ter Telgte A, Skoog I. Gustafson DR, et al. Cereb Circ Cogn Behav. 2024 May 6;6:100224. doi: 10.1016/j.cccb.2024.100224. eCollection 2024. Cereb Circ Cogn Behav. 2024. PMID: 38868624 Free PMC article. - Vascular dysfunction occurs prior to the onset of amyloid pathology and Aβ plaque deposits colocalize with endothelial cells in the hippocampus of female APPswe/PSEN1dE9 mice.
Waigi EW, Pernomian L, Crockett AM, Costa TJ, Townsend P Jr, Webb RC, McQuail JA, McCarthy CG, Hollis F, Wenceslau CF. Waigi EW, et al. Geroscience. 2024 Dec;46(6):5517-5536. doi: 10.1007/s11357-024-01213-0. Epub 2024 Jun 11. Geroscience. 2024. PMID: 38862757 Free PMC article. - Evaluating the effect of rapamycin treatment in Alzheimer's disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol.
Svensson JE, Bolin M, Thor D, Williams PA, Brautaset R, Carlsson M, Sörensson P, Marlevi D, Spin-Neto R, Probst M, Hagman G, Morén AF, Kivipelto M, Plavén-Sigray P. Svensson JE, et al. BMC Neurol. 2024 Apr 4;24(1):111. doi: 10.1186/s12883-024-03596-1. BMC Neurol. 2024. PMID: 38575854 Free PMC article. - Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.
Bermejo-Pareja F, Del Ser T. Bermejo-Pareja F, et al. J Clin Med. 2024 Jan 17;13(2):536. doi: 10.3390/jcm13020536. J Clin Med. 2024. PMID: 38256670 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- G1100540/MRC_/Medical Research Council/United Kingdom
- G0900652/MRC_/Medical Research Council/United Kingdom
- G0502157/MRC_/Medical Research Council/United Kingdom
- G0700718/MRC_/Medical Research Council/United Kingdom
- G0400074/MRC_/Medical Research Council/United Kingdom
- NS054047/NS/NINDS NIH HHS/United States
- G0500247/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical